AbbVie’s Parkinson’s Disease Therapy Rejected By US FDA

AbbVie’s Parkinson’s Disease Therapy Rejected By US FDA

AbbVie announced that the FDA has rejected its application for ABBV-951 to control motor fluctuations in advanced Parkinson’s disease patients. Foscarbidopa and foslevodopa, the prodrugs for the widely used carbidopa and levodopa, respectively, are already included in AbbVie’s Duopa as part of the treatment. Prodrugs are versions of drugs that work once they are in […]

Continue Reading